{"id":"W2793782219","doi":"10.1200/jco.2018.36.6_suppl.472","title":"Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Medicine; Bladder cancer; Willingness to pay; Cost effectiveness; Oncology; Internal medicine; Quality-adjusted life year; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003285543,0.0007997032,0.001141538,0.0008920166,0.0002777872,0.001520779,0.0007592559,0.001101978,0.003128044],"category_scores_gemma":[0.009873825,0.000720576,0.0029372,0.000760029,0.0004148932,0.001232082,0.0007889915,0.001468735,0.0001538579],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007042139,"about_ca_system_score_gemma":0.004178798,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02706429,"about_ca_topic_score_gemma":0.01680321,"domain_scores_codex":[0.9986874,0.0008757337,0.00005176113,0.0001023149,0.0001435718,0.0001391234],"domain_scores_gemma":[0.9969933,0.002254839,0.000431078,0.00005352881,0.0001138564,0.0001534285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.00718311,0.0003762924,0.0254806,0.001017116,0.002505219,0.0004367445,0.00007562489,0.9227988,0.0009262402,0.005042515,0.001514324,0.03264347],"study_design_scores_gemma":[0.002477728,0.003241861,0.03135856,0.000829606,0.004057481,0.0009884789,0.0001725136,0.9432685,0.001500102,0.008652187,0.00336649,0.00008635288],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9493598,0.01341829,0.01730488,0.003052278,0.0001039172,0.00134795,0.005372893,0.0001148596,0.009925157],"genre_scores_gemma":[0.9962269,0.000975266,0.001598803,0.0001260101,0.000008707389,0.0001399725,0.0005053051,0.000006821485,0.0004123875],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02706429,"threshold_uncertainty_score":0.05381352,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1857252760123133,"score_gpt":0.5304688733149896,"score_spread":0.3447435973026763,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}